AA
MRNS

ALPS Advisors’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

ALPS Advisors’s Portfolio MRNS Stock Details MRNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-32,691
Closed -$226K – 1039
2023
Q1 		$226K Buy
32,691
+313
+1% +$1.96K ﹤0.01% 970
2022
Q4 		$129K Buy
+32,378
New +$159K ﹤0.01% 1012
2018
Q4 		– Sell
-17,927
Closed -$717K – 959
2018
Q3 		$717K Buy
17,927
+3,227
+22% +$91.8K ﹤0.01% 462
2018
Q2 		$416K Buy
+14,700
New +$326K ﹤0.01% 747

Other funds holding MRNS

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
GC
GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return

ALPS Advisors's MRNS Position: Q2 2023 in Review

ALPS Advisors sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q2 2023, closing a stake of 32,691 shares — an estimated $226K sold.

ALPS Advisors first reported a position in MRNS in Q2 2018 and held it in 4 quarters. The position peaked at $717K in Q3 2018. 106 funds tracked by Wall St. Rank hold MRNS as of Q2 2023.

  • ALPS Advisors reported no remaining Marinus Pharmaceuticals, Inc position as of Q2 2023 after selling out during the quarter.
  • ALPS Advisors sold 32,691 Marinus Pharmaceuticals, Inc shares in Q2 2023, an estimated $226K.
  • ALPS Advisors first reported a position in Marinus Pharmaceuticals, Inc in Q2 2018 and held it in 4 quarters.
  • ALPS Advisors's Marinus Pharmaceuticals, Inc position peaked at $717K in Q3 2018.
  • 106 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q2 2023.

Based on ALPS Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.